

AGIOS PHARMACEUTICALS INC  
Form 8-K  
November 19, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 18, 2014**

**Agios Pharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**38 Sidney Street, 2<sup>nd</sup> Floor, Cambridge, MA**

**001-36014**  
**(Commission**

**File Number)**

**26-0662915**  
**(IRS Employer**

**Identification No.)**

**02139**

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (617) 649-8600

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On November 18, 2014, Agios Pharmaceuticals, Inc. issued a press release announcing initial phase 1 data on AG-120, its first-in-class inhibitor of IDH1 mutations in patients with advanced hematologic malignancies, including acute myeloid leukemia. The Company presented this data on November 19, 2014 at the 26<sup>th</sup> Annual EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research) symposium on Molecular Targets and Cancer Therapeutics. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit

No.	Description
99.1	Press release issued by Agios Pharmaceuticals, Inc. on November 18, 2014.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**AGIOS PHARMACEUTICALS, INC.**

Date: November 19, 2014

By: /s/ Glenn Goddard  
Glenn Goddard

Senior Vice President of Finance

**EXHIBIT INDEX**

Exhibit	Description
No.	
99.1	Press release issued by Agios Pharmaceuticals, Inc. on November 18, 2014.